Cargando...
Surveillance of Adverse Events After the First Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture (Flucelvax®) Reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015
BACKGROUND: In November 2012, the first cell cultured influenza vaccine, a trivalent subunit inactivated influenza vaccine (Flucelvax®, ccIIV3), was approved in the US for adults aged ≥18 years. OBJECTIVE: To assess adverse events (AEs) after ccIIV3 reported to the US Vaccine Adverse Event Reporting...
Gardado en:
| Publicado en: | Vaccine |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6500456/ https://ncbi.nlm.nih.gov/pubmed/26518405 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2015.10.084 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|